Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Liabilities and Shareholders Equity (2017 - 2025)

Selectis Health's Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $33.3 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 1.96% year-over-year to $33.3 million; the TTM value through Sep 2025 reached $134.9 million, down 10.6%, while the annual FY2024 figure was $33.4 million, 17.76% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $33.3 million at Selectis Health, down from $33.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $48.7 million in Q1 2023 and bottomed at $33.3 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $42.5 million (2022), against an average of $41.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity grew 11.73% in 2021 before it fell 21.75% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $46.9 million in 2021, then decreased by 9.45% to $42.5 million in 2022, then dropped by 4.28% to $40.7 million in 2023, then decreased by 17.76% to $33.4 million in 2024, then decreased by 0.55% to $33.3 million in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Liabilities and Shareholders Equity are $33.3 million (Q3 2025), $33.6 million (Q2 2025), and $34.5 million (Q1 2025).